Shares of Luceco plc (LON:LUCE – Get Free Report) rose 15.7% on Thursday . The company traded as high as GBX 144.80 ($1.78) and last traded at GBX 144.80 ($1.78). Approximately 1,041,821 shares were traded during mid-day trading, an increase of 281% from the average daily volume of 273,346 shares. The stock had previously closed at GBX 125.20 ($1.54).
Luceco Price Performance
The company has a debt-to-equity ratio of 55.91, a quick ratio of 1.51 and a current ratio of 2.18. The company has a market cap of £218.36 million, a price-to-earnings ratio of 1,179.83, a PEG ratio of 0.62 and a beta of 1.29. The business has a fifty day moving average price of GBX 127.43 and a 200 day moving average price of GBX 144.21.
Insiders Place Their Bets
In other news, insider Petrus R. M. Vervaat purchased 50,000 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was bought at an average cost of GBX 132 ($1.63) per share, for a total transaction of £66,000 ($81,250.77). Also, insider Will Hoy acquired 37,953 shares of Luceco stock in a transaction that occurred on Monday, November 4th. The shares were purchased at an average price of GBX 135 ($1.66) per share, for a total transaction of £51,236.55 ($63,075.90). Insiders own 57.82% of the company’s stock.
About Luceco
Luceco plc manufactures and distributes wiring accessories and LED lighting and portable power products in the United Kingdom, Europe, the Middle East, the Americas, the Asia Pacific, and Africa. It offers wiring accessories, including switches and sockets, circuit protection products, outdoor wiring devices, junction boxes, cable management products, and commercial power and accessories under the British General and Nexus brands.
Featured Articles
- Five stocks we like better than Luceco
- How to Invest in Blue Chip Stocks
- 2 ETFs to Maximize Gains With Covered Call Strategies
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Small-Cap Stocks Insiders and Institutions Are Buying
- How to Plot Fibonacci Price Inflection Levels
- MaxCyte: Building the Future of Cell and Gene Therapy Innovation
Receive News & Ratings for Luceco Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luceco and related companies with MarketBeat.com's FREE daily email newsletter.